{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:40:16Z","timestamp":1792586416534,"version":"4.5.0"},"reference-count":63,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2014.0139","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T05:19:26Z","timestamp":1525238366000},"source":"Crossref","is-referenced-by-count":16,"title":["Effects and Risks Associated with Novel Psychoactive Substances"],"prefix":"10.3238","author":[{"given":"Nicolas","family":"Hohmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Czock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2014,2,28]]},"reference":[{"key":"10.3238\/arztebl.2014.0139_ref1","unstructured":"Europ\u00e4ische Beobachtungsstelle f\u00fcr Drogen und Drogensucht: Drogenangebot in Europa. In: Europ\u00e4ischer Drogenbericht 2013: Trends und Entwicklungen. Luxemburg: Amt f\u00fcr Ver\u00f6ffentlichungen der Europ\u00e4ischen Union 2013; 28\u20139."},{"key":"10.3238\/arztebl.2014.0139_ref2","unstructured":"Nobis: \u201eLegaI-High\u201d-Produkte \u2013 wirklich illegal? \u2013 Oder: Wie ein Aufsatz sich verselbstst\u00e4ndigt! NStZ 2012; 422."},{"key":"10.3238\/arztebl.2014.0139_ref3","doi-asserted-by":"crossref","unstructured":"Fattore L, Fratta W, Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci 2011; 5: 60.","DOI":"10.3389\/fnbeh.2011.00060"},{"key":"10.3238\/arztebl.2014.0139_ref4","unstructured":"Bernhard C, Werse B, Schell-Mack C: Jahresbericht MoSyD. Drogentrends in Frankfurt am Main 2012. Centre for Drug Research 2013."},{"key":"10.3238\/arztebl.2014.0139_ref5","doi-asserted-by":"crossref","unstructured":"Hermanns-Clausen M, Kneisel S, Szabo B, Auw\u00e4rter V: Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction 2013; 108: 534\u201344.","DOI":"10.1111\/j.1360-0443.2012.04078.x"},{"key":"10.3238\/arztebl.2014.0139_ref6","doi-asserted-by":"crossref","unstructured":"Musshoff F, Madea B, Kernbach-Wighton G, et al.: Driving under the influence of synthetic cannabinoids (\u201eSpice\u201c): a case series. Int J Legal Med 2014: 128: 59\u201364.","DOI":"10.1007\/s00414-013-0864-1"},{"key":"10.3238\/arztebl.2014.0139_ref7","doi-asserted-by":"crossref","unstructured":"Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K: Withdrawal phenomena and dependence syndrome after the consumption of \u201espice gold\u201c. Dtsch Arztebl Int 2009; 106: 464\u20137.","DOI":"10.3238\/arztebl.2009.0464"},{"key":"10.3238\/arztebl.2014.0139_ref8","doi-asserted-by":"crossref","unstructured":"Glennon RA, Yousif M, Naiman N, Kalix P: Methcathinone: a new and potent amphetamine-like agent. Pharmacol Biochem Behav 1987; 26: 547\u201351.","DOI":"10.1016\/0091-3057(87)90164-X"},{"key":"10.3238\/arztebl.2014.0139_ref9","doi-asserted-by":"crossref","unstructured":"Kelly JP: Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011; 3: 439\u201353.","DOI":"10.1002\/dta.313"},{"key":"10.3238\/arztebl.2014.0139_ref10","doi-asserted-by":"crossref","unstructured":"Karila L, Reynaud M: GHB and synthetic cathinones: clinical effects and potential consequences. Drug Test Anal 2011; 3: 552\u20139.","DOI":"10.1002\/dta.210"},{"key":"10.3238\/arztebl.2014.0139_ref11","doi-asserted-by":"crossref","unstructured":"Winstock A, Mitcheson L, Ramsey J, Davies S, Puchnarewicz M, Marsden J: Mephedrone: use, subjective effects and health risks. Addiction 2011; 106: 1991\u20136.","DOI":"10.1111\/j.1360-0443.2011.03502.x"},{"key":"10.3238\/arztebl.2014.0139_ref12","doi-asserted-by":"crossref","unstructured":"Wood KE: Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr 2013; 163: 213\u20136.","DOI":"10.1016\/j.jpeds.2012.12.056"},{"key":"10.3238\/arztebl.2014.0139_ref13","doi-asserted-by":"crossref","unstructured":"Spiller HA, Ryan ML, Weston RG, Jansen J: Clinical experience with and analytical confirmation of \u201ebath salts\u201c and \u201elegal highs\u201c (synthetic cathinones) in the United States. Clin Toxicol 2011; 49: 499\u2013505.","DOI":"10.3109\/15563650.2011.590812"},{"key":"10.3238\/arztebl.2014.0139_ref14","doi-asserted-by":"crossref","unstructured":"Marinetti LJ, Antonides HM: Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and Interpretation of Results. J Anal Toxicol 2013; 37: 135\u201346.","DOI":"10.1093\/jat\/bks136"},{"key":"10.3238\/arztebl.2014.0139_ref15","doi-asserted-by":"crossref","unstructured":"Schifano F, Albanese A, Fergus S, et al. and Psychonaut Web Mapping, ReDNet Research Groups: Mephedrone (4-methylmethcathinone; \u2019meow meow\u2019): chemical, pharmacological and clinical issues. Psychopharmacology 2011; 214: 593\u2013602.","DOI":"10.1007\/s00213-010-2070-x"},{"key":"10.3238\/arztebl.2014.0139_ref16","doi-asserted-by":"crossref","unstructured":"Ross EA, Watson M, Goldberger B: \u201eBath salts\u201c intoxication. N Engl J Med 2011; 365: 967\u20138.","DOI":"10.1056\/NEJMc1107097"},{"key":"10.3238\/arztebl.2014.0139_ref17","doi-asserted-by":"crossref","unstructured":"Freeman TP, Morgan CJ, Vaughn-Jones J, Hussain N, Karimi K, Curran HV: Cognitive and subjective effects of mephedrone and factors influencing use of a \u2019new legal high\u2019. Addiction 2012; 107: 792\u2013800.","DOI":"10.1111\/j.1360-0443.2011.03719.x"},{"key":"10.3238\/arztebl.2014.0139_ref18","doi-asserted-by":"crossref","unstructured":"Belton P, Sharngoe T, Maguire FM, Polhemus M: Cardiac infection and sepsis in 3 intravenous bath salts drug users. Clin Infect Dis 2013; 56: e102\u20134.","DOI":"10.1093\/cid\/cit095"},{"key":"10.3238\/arztebl.2014.0139_ref19","doi-asserted-by":"crossref","unstructured":"Wood DM, Davies S, Greene SL, et al.: Case series of individuals with analytically confirmed acute mephedrone toxicity. Clin Toxicol 2010; 48: 924\u20137.","DOI":"10.3109\/15563650.2010.531021"},{"key":"10.3238\/arztebl.2014.0139_ref20","doi-asserted-by":"crossref","unstructured":"Murphy CM, Dulaney AR, Beuhler MC, Kacinko S: \u201eBath salts\u201c and \u201eplant food\u201c products: the experience of one regional US poison center. J Med Toxicol 2013; 9: 42\u20138.","DOI":"10.1007\/s13181-012-0243-1"},{"key":"10.3238\/arztebl.2014.0139_ref21","doi-asserted-by":"crossref","unstructured":"Penders TM, Gestring RE, Vilensky DA: Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry 2012; 34: 647\u201350.","DOI":"10.1016\/j.genhosppsych.2012.06.005"},{"key":"10.3238\/arztebl.2014.0139_ref22","doi-asserted-by":"crossref","unstructured":"Nicholson PJ, Quinn MJ, Dodd JD: Headshop heartache: acute mephedrone \u2019meow\u2019 myocarditis. Heart 2010; 96: 2051\u20132.","DOI":"10.1136\/hrt.2010.209338"},{"key":"10.3238\/arztebl.2014.0139_ref23","doi-asserted-by":"crossref","unstructured":"Loeffler G, Penn A, Ledden B: \u201eBath salt\u201c-induced agitated paranoia: a case series. J Stud Alcohol Drugs 2012; 73: 706.","DOI":"10.15288\/jsad.2012.73.706"},{"key":"10.3238\/arztebl.2014.0139_ref24","doi-asserted-by":"crossref","unstructured":"Borek HA, Holstege CP: Hyperthermia and multiorgan failure after abuse of \u201ebath salts\u201c containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med 2012; 60: 103\u20135.","DOI":"10.1016\/j.annemergmed.2012.01.005"},{"key":"10.3238\/arztebl.2014.0139_ref25","doi-asserted-by":"crossref","unstructured":"Schifano F, Corkery J, Ghodse AH: Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, \u201emeow meow\u201c) in the United Kingdom. J Clin Psychopharmacol 2012; 32: 710\u20134.","DOI":"10.1097\/JCP.0b013e318266c70c"},{"key":"10.3238\/arztebl.2014.0139_ref26","unstructured":"Centers for Disease Control and Prevention: Acute kidney injury associated with synthetic cannabinoid use-multiple states 2012. MMWR Morb Mortal Wkly Rep 2013; 62: 93\u20138."},{"key":"10.3238\/arztebl.2014.0139_ref27","doi-asserted-by":"crossref","unstructured":"Auw\u00e4rter V, Dresen S, Weinmann W, M\u00fcller M, P\u00fctz M, Ferreir\u00f3s N: \u2019Spice\u2019 and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 2009; 44: 832\u20137.","DOI":"10.1002\/jms.1558"},{"key":"10.3238\/arztebl.2014.0139_ref28","doi-asserted-by":"crossref","unstructured":"Seely KA, Prather PL, James LP, Moran JH: Marijuana-based drugs: innovative therapeutics or designer drugs of abuse? Mol Interv 2011; 11: 36\u201351.","DOI":"10.1124\/mi.11.1.6"},{"key":"10.3238\/arztebl.2014.0139_ref29","doi-asserted-by":"crossref","unstructured":"Simolka K, Lindigkeit R, Schiebel HM, Papke U, Ernst L, Beuerle T: Analysis of synthetic cannabinoids in \u201espice-like\u201c herbal highs: snapshot of the German market in summer 2011. Anal Bioanal Chem 2012; 404: 157\u201371.","DOI":"10.1007\/s00216-012-6122-4"},{"key":"10.3238\/arztebl.2014.0139_ref30","doi-asserted-by":"crossref","unstructured":"Hillebrand J, Olszewski D, Sedefov R: Legal highs on the internet. Subst Use Misuse 2010; 45: 330\u201340.","DOI":"10.3109\/10826080903443628"},{"key":"10.3238\/arztebl.2014.0139_ref31","doi-asserted-by":"crossref","unstructured":"Griffiths P, Sedefov R, Gallegos A, Lopez D: How globalization and market innovation challenge how we think about and respond to drug use: \u2019Spice\u2019 a case study. Addiction 2010; 105: 951\u20133.","DOI":"10.1111\/j.1360-0443.2009.02874.x"},{"key":"10.3238\/arztebl.2014.0139_ref32","doi-asserted-by":"crossref","unstructured":"M\u00fcller H, Sperling W, K\u00f6hrmann M, Huttner HB, Kornhuber J, Maler JM: The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118: 309\u201310.","DOI":"10.1016\/j.schres.2009.12.001"},{"key":"10.3238\/arztebl.2014.0139_ref33","doi-asserted-by":"crossref","unstructured":"de Boer D, Bosman IJ, Hidvegi E, et al.: Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. For Sci Int 2001; 121: 47\u201356.","DOI":"10.1016\/S0379-0738(01)00452-2"},{"key":"10.3238\/arztebl.2014.0139_ref34","doi-asserted-by":"crossref","unstructured":"Elliott S: Current awareness of piperazines: pharmacology and toxicology. Drug Test Anal 2011; 3: 430\u20138.","DOI":"10.1002\/dta.307"},{"key":"10.3238\/arztebl.2014.0139_ref35","doi-asserted-by":"crossref","unstructured":"Thompson I, Williams G, Caldwell B, et al.: Randomised double-blind, placebo-controlled trial of the effects of the \u2019party pills\u2019 BZP\/TFMPP alone and in combination with alcohol. J Psychopharmacol 2010; 24: 1299\u2013308.","DOI":"10.1177\/0269881109102608"},{"key":"10.3238\/arztebl.2014.0139_ref36","doi-asserted-by":"crossref","unstructured":"Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P: Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol 2008; 46: 802\u20137.","DOI":"10.1080\/15563650802307602"},{"key":"10.3238\/arztebl.2014.0139_ref37","doi-asserted-by":"crossref","unstructured":"Coppola M, Mondola R: 5-iodo-2-aminoindan (5-IAI): chemistry, pharmacology, and toxicology of a research chemical producing MDMA-like effects. Toxicol Lett 2013; 218: 24\u20139.","DOI":"10.1016\/j.toxlet.2013.01.008"},{"key":"10.3238\/arztebl.2014.0139_ref38","doi-asserted-by":"crossref","unstructured":"Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA: Aminoindanes-the next wave of \u2019legal highs\u2019? Drug Test Anal 2011; 3: 479\u201382.","DOI":"10.1002\/dta.318"},{"key":"10.3238\/arztebl.2014.0139_ref39","doi-asserted-by":"crossref","unstructured":"Corazza O, Schifano F, Farre M, et al.: Designer drugs on the internet: a phenomenon out-of-control? The emergence of hallucinogenic drug Bromo-Dragonfly. Curr Clin Pharmacol 2011; 6: 125\u20139.","DOI":"10.2174\/157488411796151129"},{"key":"10.3238\/arztebl.2014.0139_ref40","unstructured":"Thorlacius K, Borna C, Personne M: Bromo-dragon fly\u2014life-threatening drug. Can cause tissue necrosis as demonstrated by the first described case. Lakartidningen 2008; 105: 1199\u2013200."},{"key":"10.3238\/arztebl.2014.0139_ref41","doi-asserted-by":"crossref","unstructured":"Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA: Designer drugs: a medicinal chemistry perspective. Ann N Y Acad Sci 2012; 1248: 18\u201338.","DOI":"10.1111\/j.1749-6632.2011.06199.x"},{"key":"10.3238\/arztebl.2014.0139_ref42","doi-asserted-by":"crossref","unstructured":"Corazza O, Demetrovics Z, van den Brink W, Schifano F: \u2019Legal highs\u2019 an inappropriate term for \u2019Novel Psychoactive Drugs\u2019 in drug prevention and scientific debate. Int J Drug Policy 2013; 24: 82\u20133.","DOI":"10.1016\/j.drugpo.2012.06.005"},{"key":"10.3238\/arztebl.2014.0139_ref43","doi-asserted-by":"crossref","unstructured":"Rosenbaum CD, Carreiro SP, Babu KM: Here today, gone tomorrow\u2026and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines. J Med Toxicol 2012; 8: 15\u201332.","DOI":"10.1007\/s13181-011-0202-2"},{"key":"10.3238\/arztebl.2014.0139_ref44","doi-asserted-by":"crossref","unstructured":"Meyer MR, Wilhelm J, Peters FT, Maurer HH: Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylone in urine using gas chromatography-mass spectrometry. Anal Bioanal Chem 2010; 397: 1225\u201333.","DOI":"10.1007\/s00216-010-3636-5"},{"key":"10.3238\/arztebl.2014.0139_ref45","doi-asserted-by":"crossref","unstructured":"Kneisel S, Auw\u00e4rter V, Kempf J: Analysis of 30 synthetic cannabinoids in oral fluid using liquid chromatography-electrospray ionization tandem mass spectrometry. Drug Test Anal 2013; 5: 657\u201369.","DOI":"10.1002\/dta.1429"},{"key":"10.3238\/arztebl.2014.0139_ref46","doi-asserted-by":"crossref","unstructured":"Graziani M, Milella MS, Nencini P: Khat chewing from the pharmacological point of view: an update. Subst Use Misuse 2008; 43: 762\u201383.","DOI":"10.1080\/10826080701738992"},{"key":"10.3238\/arztebl.2014.0139_ref47","doi-asserted-by":"crossref","unstructured":"Goldberg J, Gardos G, Cole JO: A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int Pharmacopsychiatry 1973; 8: 60\u20139.","DOI":"10.1159\/000467975"},{"key":"10.3238\/arztebl.2014.0139_ref48","doi-asserted-by":"crossref","unstructured":"Baron M, Elie M, Elie L: An analysis of legal highs: do they contain what it says on the tin? Drug Test Anal 2011; 3: 576\u201381.","DOI":"10.1002\/dta.274"},{"key":"10.3238\/arztebl.2014.0139_ref49","doi-asserted-by":"crossref","unstructured":"Maxwell JC: Psychoactive substances-Some new, some old: A scan of the situation in the U.S. Drug Alcohol Depend 2013 [in Press].","DOI":"10.1016\/j.drugalcdep.2013.09.011"},{"key":"10.3238\/arztebl.2014.0139_ref50","doi-asserted-by":"crossref","unstructured":"Simmler LD, Buser TA, Donzelli M, et al.: Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013; 168: 458\u201370.","DOI":"10.1111\/j.1476-5381.2012.02145.x"},{"key":"10.3238\/arztebl.2014.0139_ref51","doi-asserted-by":"crossref","unstructured":"Zawilska JB, Wojcieszak J: Designer cathinones-an emerging class of novel recreational drugs. Forensic Sci Int 2013; 231: 42\u201353.","DOI":"10.1016\/j.forsciint.2013.04.015"},{"key":"10.3238\/arztebl.2014.0139_ref52","doi-asserted-by":"crossref","unstructured":"James D, Adams RD, Spears R, et al.: Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg Med J 2011; 28: 686\u20139.","DOI":"10.1136\/emj.2010.096636"},{"key":"10.3238\/arztebl.2014.0139_ref53","doi-asserted-by":"crossref","unstructured":"Nakagawa Y, Suzuki T, Tayama S, Ishii H, Ogata A: Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch Toxicol 2009; 83: 69\u201380.","DOI":"10.1007\/s00204-008-0323-9"},{"key":"10.3238\/arztebl.2014.0139_ref54","doi-asserted-by":"crossref","unstructured":"Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585\u20139.","DOI":"10.1038\/nn1457"},{"key":"10.3238\/arztebl.2014.0139_ref55","doi-asserted-by":"crossref","unstructured":"Randall MD, Kendall DA, O\u2019Sullivan S: The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 2004; 142: 20\u20136.","DOI":"10.1038\/sj.bjp.0705725"},{"key":"10.3238\/arztebl.2014.0139_ref56","doi-asserted-by":"crossref","unstructured":"Atwood BK, Huffman J, Straiker A, Mackie K: JWH018, a common constituent of \u2019Spice\u2019 herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol 2010; 160: 585\u201393.","DOI":"10.1111\/j.1476-5381.2009.00582.x"},{"key":"10.3238\/arztebl.2014.0139_ref57","doi-asserted-by":"crossref","unstructured":"Psychoyos D, Vinod KY: Marijuana, Spice \u2019herbal high\u2019, and early neural development: implications for rescheduling and legalization. Drug Test Anal 2013; 5: 27\u201345.","DOI":"10.1002\/dta.1390"},{"key":"10.3238\/arztebl.2014.0139_ref58","doi-asserted-by":"crossref","unstructured":"Forrester MB: Synthetic cathinone exposures reported to Texas poison centers. Am J Drug Alcohol Abuse 2012; 38: 609\u201315.","DOI":"10.3109\/00952990.2012.677890"},{"key":"10.3238\/arztebl.2014.0139_ref59","doi-asserted-by":"crossref","unstructured":"Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL: \u201eSpice\u201c and \u201eK2\u201c herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 2012; 21: 320\u20136.","DOI":"10.1111\/j.1521-0391.2012.00240.x"},{"key":"10.3238\/arztebl.2014.0139_ref60","doi-asserted-by":"crossref","unstructured":"Corkery JM, Elliott S, Schifano F, Corazza O, Ghodse AH: MDAI (5,6-methylenedioxy-2-aminoindane; 6,7-dihydro-5H-cyclopenta[f][1,3]benzodioxol-6-amine; \u2019sparkle\u2019; \u2019mindy\u2019) toxicity: a brief overview and update. Hum Psychopharmacol 2013; 28: 345\u201355.","DOI":"10.1002\/hup.2298"},{"key":"10.3238\/arztebl.2014.0139_ref61","unstructured":"Psychonaut Web Mapping Group: Bromo-Dragonfly Report. London UK: Institute of Psychiatry, King\u2019s College London; 2009."},{"key":"10.3238\/arztebl.2014.0139_ref62","unstructured":"United Nations Office on Drugs and Crime (UNODC): Details for Piperazines. www.unodc.org\/LSS\/SubstanceGroup\/Details\/ 8242b801\u2013355c-4454\u20139fdc-ba4b7e7689d5#_ftn11 (last accessed on 4 December 2013)."},{"key":"10.3238\/arztebl.2014.0139_ref63","doi-asserted-by":"crossref","unstructured":"Hill SL, Thomas SH: Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011; 49: 705\u201319.","DOI":"10.3109\/15563650.2011.615318"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2014.0139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T08:17:37Z","timestamp":1638778657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2014.0139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,28]]},"references-count":63,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2014.0139","relation":{"is-cited-by":[{"id-type":"doi","id":"10.1080\/02791072.2016.1207827","asserted-by":"object"},{"id-type":"doi","id":"10.1007\/978-3-642-55125-3_13","asserted-by":"object"},{"id-type":"doi","id":"10.3389\/fnins.2016.00153","asserted-by":"object"},{"id-type":"doi","id":"10.1155\/2015\/180921","asserted-by":"object"}]},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,28]]}}}